Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.10.2023 | Case report

Baricitinib

Multi-dermatomal herpes zoster: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat King B, et al. Safety Analysis of Baricitinib in Adult Patients with Severe Alopecia Areata From 2 Randomized Clinical Trials over a Median of 1.6 years and up to 3.6 Years of Exposure. Journal of the American Academy of Dermatology 89 (Suppl.): AB220 abstr. 43018, No. 3, Sep 2023. Available from: URL: http://doi.org/10.1016/j.jaad.2023.07.882 [abstract] King B, et al. Safety Analysis of Baricitinib in Adult Patients with Severe Alopecia Areata From 2 Randomized Clinical Trials over a Median of 1.6 years and up to 3.6 Years of Exposure. Journal of the American Academy of Dermatology 89 (Suppl.): AB220 abstr. 43018, No. 3, Sep 2023. Available from: URL: http://​doi.​org/​10.​1016/​j.​jaad.​2023.​07.​882 [abstract]
Metadaten
Titel
Baricitinib
Multi-dermatomal herpes zoster: case report
Publikationsdatum
01.10.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-47814-x

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Interferon-beta

Case report

Sunitinib

Case report

Tirzepatide

Case report

Ebastine abuse

Case report

Sirolimus